Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2008

Open Access 01-12-2008 | Research

Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers

Authors: Terje Ahlquist, Guro E Lind, Vera L Costa, Gunn I Meling, Morten Vatn, Geir S Hoff, Torleiv O Rognum, Rolf I Skotheim, Espen Thiis-Evensen, Ragnhild A Lothe

Published in: Molecular Cancer | Issue 1/2008

Login to get access

Abstract

Background

Multiple epigenetic and genetic changes have been reported in colorectal tumors, but few of these have clinical impact. This study aims to pinpoint epigenetic markers that can discriminate between non-malignant and malignant tissue from the large bowel, i.e. markers with diagnostic potential.
The methylation status of eleven genes (ADAMTS1, CDKN2A, CRABP1, HOXA9, MAL, MGMT, MLH1, NR3C1, PTEN, RUNX3, and SCGB3A1) was determined in 154 tissue samples including normal mucosa, adenomas, and carcinomas of the colorectum. The gene-specific and widespread methylation status among the carcinomas was related to patient gender and age, and microsatellite instability status. Possible CIMP tumors were identified by comparing the methylation profile with microsatellite instability (MSI), BRAF-, KRAS-, and TP53 mutation status.

Results

The mean number of methylated genes per sample was 0.4 in normal colon mucosa from tumor-free individuals, 1.2 in mucosa from cancerous bowels, 2.2 in adenomas, and 3.9 in carcinomas. Widespread methylation was found in both adenomas and carcinomas. The promoters of ADAMTS1, MAL, and MGMT were frequently methylated in benign samples as well as in malignant tumors, independent of microsatellite instability. In contrast, normal mucosa samples taken from bowels without tumor were rarely methylated for the same genes. Hypermethylated CRABP1, MLH1, NR3C1, RUNX3, and SCGB3A1 were shown to be identifiers of carcinomas with microsatellite instability. In agreement with the CIMP concept, MSI and mutated BRAF were associated with samples harboring hypermethylation of several target genes.

Conclusion

Methylated ADAMTS1, MGMT, and MAL are suitable as markers for early tumor detection.
Appendix
Available only for authorised users
Literature
1.
Ponz DL, Di Gregorio C: Pathology of colorectal cancer. Dig Liver Dis. 2001, 33: 372-388. 10.1016/S1590-8658(01)80095-5CrossRef
2.
Grady WM, Markowitz SD: Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet. 2002, 3: 101-28. Epub@2002 Apr 15.:101-128., 10.1146/annurev.genom.3.022502.103043CrossRefPubMed
3.
Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA. 1999, 96: 8681-8686. 10.1073/pnas.96.15.8681PubMedCentralCrossRefPubMed
4.
Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, Hernandez NS, Chen X, Ahmed S, Konishi K: Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA. 2007, 104: 18654-18659. 10.1073/pnas.0704652104PubMedCentralCrossRefPubMed
5.
Meling GI, Lothe RA, Børresen AL, Hauge S, Graue C, Clausen OP, Rognum TO: Genetic alterations within the retinoblastoma locus in colorectal carcinomas. Relation to DNA ploidy pattern studied by flow cytometric analysis. Br J Cancer. 1991, 64: 475-480.PubMedCentralCrossRefPubMed
6.
Thiis-Evensen E, Hoff GS, Sauar J, Langmark F, Majak BM, Vatn MH: Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I. Scand J Gastroenterol. 1999, 34: 414-420. 10.1080/003655299750026443CrossRefPubMed
7.
Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA. 1992, 89: 1827-1831. 10.1073/pnas.89.5.1827PubMedCentralCrossRefPubMed
8.
Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996, 93: 9821-9826. 10.1073/pnas.93.18.9821PubMedCentralCrossRefPubMed
9.
Lind GE, Kleivi K, Meling GI, Teixeira MR, Thiis-Evensen E, Rognum TO, Lothe RA: ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. Cell Oncol. 2006, 28: 259-272.PubMed
10.
Lind GE, Ahlquist T, Lothe RA: DNA hypermethylation of MAL: a promising diagnostic biomarker for colorectal tumors. Gastroenterology. 2007, 132: 1631-1632. 10.1053/j.gastro.2007.03.003CrossRefPubMed
11.
Lind GE, Thorstensen L, Løvig T, Meling GI, Hamelin R, Rognum TO, Esteller M, Lothe RA: A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines. Mol Cancer. 2004, 3: 28- 10.1186/1476-4598-3-28PubMedCentralCrossRefPubMed
12.
Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, Peters JH, DeMeester SR, DeMeester TR, Skinner KA: Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 2001, 61: 3410-3418.PubMed
13.
Lind GE, Ahlquist T, Kolberg M, Berg M, Eknaes M, Alonso MA, Kallioniemi A, Meling GI, Skotheim RI, Rognum TO: Hypermethylated MAL gene – a silent marker of early colon tumorigenesis. J Transl Med. 2008, 6 (13): 13- 10.1186/1479-5876-6-13PubMedCentralCrossRefPubMed
14.
Nagasaka T, Goel A, Notohara K, Takahata T, Sasamoto H, Uchida T, Nishida N, Tanaka N, Boland CR, Matsubara N: Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. Int J Cancer. 2008, 122: 2429-2436. 10.1002/ijc.23398PubMedCentralCrossRefPubMed
15.
Bai AH, Tong JH, To KF, Chan MW, Man EP, Lo KW, Lee JF, Sung JJ, Leung WK: Promoter hypermethylation of tumor-related genes in the progression of colorectal neoplasia. Int J Cancer. 2004, 112: 846-853. 10.1002/ijc.20485CrossRefPubMed
16.
Kang YH, Lee HS, Kim WH: Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest. 2002, 82: 285-291.CrossRefPubMed
17.
Baeza N, Weller M, Yonekawa Y, Kleihues P, Ohgaki H: PTEN methylation and expression in glioblastomas. Acta Neuropathol (Berl). 2003, 106: 479-485. 10.1007/s00401-003-0748-4. 10.1007/s00401-003-0748-4CrossRef
18.
Khan S, Kumagai T, Vora J, Bose N, Sehgal I, Koeffler PH, Bose S: PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer. 2004, 112: 407-410. 10.1002/ijc.20447CrossRefPubMed
19.
Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR: Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res. 2004, 64: 3014-3021. 10.1158/0008-5472.CAN-2401-2CrossRefPubMed
20.
21.
Garcia JM, Silva J, Pena C, Garcia V, Rodriguez R, Cruz MA, Cantos B, Provencio M, Espana P, Bonilla F: Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer. 2004, 41: 117-124. 10.1002/gcc.20062CrossRefPubMed
22.
Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, Compton C, Mayer RJ, Goldberg R, Bertagnolli MM: The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology. 2007, 132: 127-138. 10.1053/j.gastro.2006.09.018CrossRefPubMed
23.
Ahlquist T, Bottillo I, Danielsen SA, Meling GI, Rognum TO, Lind GE, Dallapiccola B, Lothe RA: RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A. Neoplasia. 2008, 10: 680-6. 2.PubMedCentralCrossRefPubMed
24.
Diep CB, Thorstensen L, Meling GI, Skovlund E, Rognum TO, Lothe RA: Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients. J Clin Oncol. 2003, 21: 820-829. 10.1200/JCO.2003.05.190CrossRefPubMed
25.
Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999, 59: 793-797.PubMed
26.
Krop IE, Sgroi D, Porter DA, Lunetta KL, LeVangie R, Seth P, Kaelin CM, Rhei E, Bosenberg M, Schnitt S: HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc Natl Acad Sci USA. 2001, 98: 9796-9801. 10.1073/pnas.171138398PubMedCentralCrossRefPubMed
27.
Alaminos M, Davalos V, Cheung NK, Gerald WL, Esteller M: Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst. 2004, 96: 1208-1219.CrossRefPubMed
28.
Goel A, Arnold CN, Tassone P, Chang DK, Niedzwiecki D, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM: Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer. 2004, 112: 754-759. 10.1002/ijc.20472CrossRefPubMed
29.
Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 2000, 24: 132-138. 10.1038/72785CrossRefPubMed
30.
Hayashi H, Nagae G, Tsutsumi S, Kaneshiro K, Kozaki T, Kaneda A, Sugisaki H, Aburatani H: High-resolution mapping of DNA methylation in human genome using oligonucleotide tiling array. Hum Genet. 2007, 120: 701-711. 10.1007/s00439-006-0254-6CrossRefPubMed
31.
Schuebel KE, Chen W, Cope L, Glockner SC, Suzuki H, Yi JM, Chan TA, van Neste L, van Criekinge W, van den Bosch S: Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet. 2007, 3: 1709-1723. 10.1371/journal.pgen.0030157CrossRefPubMed
32.
Kuno K, Bannai K, Hakozaki M, Matsushima K, Hirose K: The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential. Biochem Biophys Res Commun. 2004, 319: 1327-1333. 10.1016/j.bbrc.2004.05.105CrossRefPubMed
33.
34.
Novak P, Jensen T, Oshiro MM, Wozniak RJ, Nouzova M, Watts GS, Klimecki WT, Kim C, Futscher BW: Epigenetic inactivation of the HOXA gene cluster in breast cancer. Cancer Res. 2006, 66: 10664-10670. 10.1158/0008-5472.CAN-06-2761CrossRefPubMed
35.
Strathdee G, Holyoake TL, Sim A, Parker A, Oscier DG, Melo JV, Meyer S, Eden T, Dickinson AM, Mountford JC: Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res. 2007, 13: 5048-5055. 10.1158/1078-0432.CCR-07-0919CrossRefPubMed
36.
Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, Clark SJ: Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet. 2006, 38: 540-549. 10.1038/ng1781CrossRefPubMed
37.
Alonso MA, Weissman SM: cDNA cloning and sequence of MAL, a hydrophobic protein associated with human T-cell differentiation. Proc Natl Acad Sci USA. 1987, 84: 1997-2001. 10.1073/pnas.84.7.1997PubMedCentralCrossRefPubMed
38.
Marazuela M, Alonso MA: Expression of MAL and MAL2, two elements of the protein machinery for raft-mediated transport, in normal and neoplastic human tissue. Histol Histopathol. 2004, 19: 925-933.PubMed
39.
Chan AO, Broaddus RR, Houlihan PS, Issa JP, Hamilton SR, Rashid A: CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol. 2002, 160: 1823-1830.PubMedCentralCrossRefPubMed
40.
Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP: Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res. 1998, 58: 5489-5494.PubMed
41.
42.
Jass JR: Molecular heterogeneity of colorectal cancer: Implications for cancer control. Surg Oncol. 2007, 16 (Suppl 1): S7-9. Epub;%2007 Nov 26.:S7–S9., 10.1016/j.suronc.2007.10.039CrossRefPubMed
43.
Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006, 38: 787-793. 10.1038/ng1834CrossRefPubMed
44.
Lee S, Hwang KS, Lee HJ, Kim JS, Kang GH: Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab Invest. 2004, 84: 884-893. 10.1038/labinvest.3700108CrossRefPubMed
45.
Ebert MP, Mooney SH, Tonnes-Priddy L, Lograsso J, Hoffmann J, Chen J, Rocken C, Schulz HU, Malfertheiner P, Lofton-Day C: Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancers. Neoplasia. 2005, 7: 771-778. 10.1593/neo.05235PubMedCentralCrossRefPubMed
46.
Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Grieu F, Watanabe G, Iacopetta B: DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer. 2006, 94: 593-598. 10.1038/sj.bjc.6602940PubMedCentralCrossRefPubMed
47.
Minoo P, Baker K, Goswami R, Chong G, Foulkes W, Ruszkiewicz A, Barker M, Buchanan D, Young J, Jass JR: Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. Gut. 2006, 55: 1467-1474. 10.1136/gut.2005.082859PubMedCentralCrossRefPubMed
48.
Takahashi T, Shigematsu H, Shivapurkar N, Reddy J, Zheng Y, Feng Z, Suzuki M, Nomura M, Augustus M, Yin J: Aberrant promoter methylation of multiple genes during multistep pathogenesis of colorectal cancers. Int J Cancer. 2006, 118: 924-931. 10.1002/ijc.21453CrossRefPubMed
49.
Derks S, Postma C, Moerkerk PT, Bosch van den SM, Carvalho B, Hermsen MA, Giaretti W, Herman JG, Weijenberg MP, de Bruine AP: Promoter methylation precedes chromosomal alterations in colorectal cancer development. Cell Oncol. 2006, 28: 247-257.PubMed
50.
Ye C, Shrubsole MJ, Cai Q, Ness R, Grady WM, Smalley W, Cai H, Washington K, Zheng W: Promoter methylation status of the MGMT, hMLH1, and CDKN2A/p16 genes in non-neoplastic mucosa of patients with and without colorectal adenomas. Oncol Rep. 2006, 16: 429-435.PubMed
51.
Lee M, Sup HW, Kyoung KO, Hee SS, Sun CM, Lee SN, Koo H: Prognostic value of p16(INK4a) and p14(ARF) gene hypermethylation in human colon cancer. Pathol Res Pract. 2006, 202: 415-424. 10.1016/j.prp.2005.11.011CrossRefPubMed
52.
Park SJ, Rashid A, Lee JH, Kim SG, Hamilton SR, Wu TT: Frequent CpG island methylation in serrated adenomas of the colorectum. Am J Pathol. 2003, 162: 815-822.PubMedCentralCrossRefPubMed
53.
Kim HC, Lee HJ, Roh SA, Kim JS, Yu CS, Kim JC: CpG island methylation in familial colorectal cancer patients not fulfilling the Amsterdam criteria. J Korean Med Sci. 2008, 23: 270-277. 10.3346/jkms.2008.23.2.270PubMedCentralCrossRefPubMed
54.
Ishiguro A, Takahata T, Saito M, Yoshiya G, Tamura Y, Sasaki M, Munakata A: Influence of methylated p15 and p16 genes on clinicopathological features in colorectal cancer. J Gastroenterol Hepatol. 2006, 21: 1334-1339. 10.1111/j.1440-1746.2006.04137.xCrossRefPubMed
55.
Deng G, Kakar S, Tanaka H, Matsuzaki K, Miura S, Sleisenger MH, Kim YS: Proximal and distal colorectal cancers show distinct gene-specific methylation profiles and clinical and molecular characteristics. Eur J Cancer. 2008, 44: 1290-1301. 10.1016/j.ejca.2008.03.014CrossRefPubMed
56.
Belshaw NJ, Elliott GO, Foxall RJ, Dainty JR, Pal N, Coupe A, Garg D, Bradburn DM, Mathers JC, Johnson IT: Profiling CpG island field methylation in both morphologically normal and neoplastic human colonic mucosa. Br J Cancer. 2008, 99: 136-142. 10.1038/sj.bjc.6604432PubMedCentralCrossRefPubMed
57.
Petko Z, Ghiassi M, Shuber A, Gorham J, Smalley W, Washington MK, Schultenover S, Gautam S, Markowitz SD, Grady WM: Aberrantly Methylated CDKN2A, MGMT, and MLH1 in Colon Polyps and in Fecal DNA from Patients with Colorectal Polyps. Clin Cancer Res. 2005, 11: 1203-1209.PubMed
58.
Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG: MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst. 2005, 97: 1330-1338.CrossRefPubMed
59.
Cheng YW, Shawber C, Notterman D, Paty P, Barany F: Multiplexed profiling of candidate genes for CpG island methylation status using a flexible PCR/LDR/Universal Array assay. Genome Res. 2006, 16: 282-289. 10.1101/gr.4181406PubMedCentralCrossRefPubMed
60.
Huang ZH, Li LH, Yang F, Wang JF: Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J Gastroenterol. 2007, 13: 950-954.PubMedCentralCrossRefPubMed
61.
Menigatti M, Pedroni M, Verrone AM, Borghi F, Scarselli A, Benatti P, Losi L, Di GC, Schar P, Marra G: O6-methylguanine-DNA methyltransferase promoter hypermethylation in colorectal carcinogenesis. Oncol Rep. 2007, 17: 1421-1427.PubMed
62.
Koinuma K, Kaneda R, Toyota M, Yamashita Y, Takada S, Choi YL, Wada T, Okada M, Konishi F, Nagai H: Screening for genomic fragments that are methylated specifically in colorectal carcinoma with a methylated MLH1 promoter. Carcinogenesis. 2005, 26: 2078-2085. 10.1093/carcin/bgi184CrossRefPubMed
63.
Nuovo GJ, Nakagawa H, Sotamaa K, Chapelle ADL: Hypermethylation of the MLH1 promoter with concomitant absence of transcript and protein occurs in small patches of crypt cells in unaffected mucosa from sporadic colorectal carcinoma. Diagn Mol Pathol. 2006, 15: 17-23. 10.1097/00019606-200603000-00003CrossRefPubMed
64.
Ide T, Kitajima Y, Ohtaka K, Mitsuno M, Nakafusa Y, Miyazaki K: Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer. Oncol Rep. 2008, 19: 1571-1576.PubMed
65.
Hitchins MP, Lin VA, Buckle A, Cheong K, Halani N, Ku S, Kwok CT, Packham D, Suter CM, Meagher A: Epigenetic inactivation of a cluster of genes flanking MLH1 in microsatellite-unstable colorectal cancer. Cancer Res. 2007, 67: 9107-9116. 10.1158/0008-5472.CAN-07-0869CrossRefPubMed
66.
Leung WK, To KF, Man EP, Chan MW, Bai AH, Hui AJ, Chan FK, Sung JJ: Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am J Gastroenterol. 2005, 100: 2274-2279. 10.1111/j.1572-0241.2005.50412.xCrossRefPubMed
67.
Xiong Z, Wu AH, Bender CM, Tsao JL, Blake C, Shibata D, Jones PA, Yu MC, Ross RK, Laird PW: Mismatch repair deficiency and CpG island hypermethylation in sporadic colon adenocarcinomas. Cancer Epidemiol Biomarkers Prev. 2001, 10: 799-803.PubMed
68.
Muller HM, Oberwalder M, Fiegl H, Morandell M, Goebel G, Zitt M, Muhlthaler M, Ofner D, Margreiter R, Widschwendter M: Methylation changes in faecal DNA: a marker for colorectal cancer screening?. Lancet. 2004, 363: 1283-1285. 10.1016/S0140-6736(04)16002-9CrossRefPubMed
69.
Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, Platzer P, Lu S, Dawson D, Willis J: Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst. 2005, 97: 1124-1132.CrossRefPubMed
70.
Giovannucci E, Ogino S: DNA methylation, field effects, and colorectal cancer. J Natl Cancer Inst. 2005, 97: 1317-1319.CrossRefPubMed
71.
Feinberg AP, Ohlsson R, Henikoff S: The epigenetic progenitor origin of human cancer. Nat Rev Genet. 2006, 7: 21-33. 10.1038/nrg1748CrossRefPubMed
Metadata
Title
Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers
Authors
Terje Ahlquist
Guro E Lind
Vera L Costa
Gunn I Meling
Morten Vatn
Geir S Hoff
Torleiv O Rognum
Rolf I Skotheim
Espen Thiis-Evensen
Ragnhild A Lothe
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2008
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-7-94

Other articles of this Issue 1/2008

Molecular Cancer 1/2008 Go to the issue

Research

Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: Pathological significance in early- and late-onset breast carcinoma

Research

Differential effects of energy stress on AMPK phosphorylation and apoptosis in experimental brain tumor and normal brain

Research

The parafibromin tumor suppressor protein interacts with actin-binding proteins actinin-2 and actinin-3

Review

Evaluation of cell types for assessment of cytogenetic damage in arsenic exposed population

Editorial

To know or not to know: archiving and the under-appreciated historical value of data

Research

ret/PTC-1 expression alters the immunoprofile of thyroid follicular cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits